HIV/AIDS News Releases

NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks with HIV
August 30, 2017

Scientists at the National Institutes of Health have expanded the understanding of how chronic inflammation and persistent immune activation associated with HIV infection drive cardiovascular disease risk in people living with HIV. People living with HIV are up to twice as likely to experience heart attacks, strokes and other forms of cardiovascular disease as people who do not have the virus, even when HIV infection is well-controlled with the use of antiretroviral therapy. 

In Adolescents, Oral Truvada and Vaginal Ring for HIV Prevention Are Safe, Acceptable
July 25, 2017

A monthly vaginal ring and a daily oral tablet, both containing anti-HIV drugs, were safe and acceptable in studies of adolescents, two teams of investigators reported today at the 9th IAS Conference on HIV Science in Paris. The experimental ring is designed for HIV prevention and the oral tablet is already used for this purpose in adults. Adherence to the ring was high, while adherence to the tablet was moderate and diminished substantially when study visits became less frequent.

Drug Interaction Concerns May Negatively Affect HIV Treatment Adherence Among Transgender Women
July 24, 2017

Transgender women—people whose birth certificates indicate or once indicated male sex but who identify as women—are at high risk of HIV acquisition, and thus are a key population for HIV prevention and treatment efforts.

Child Living with HIV Maintains Remission Without Drugs Since 2008
July 24, 2017

A nine-year-old South African child who was diagnosed with HIV infection at one month of age and received anti-HIV treatment during infancy has suppressed the virus without anti-HIV drugs for eight and a half years, scientists reported today at the 9th IAS Conference on HIV Science in Paris. This case appears to be the third reported instance of sustained HIV remission in a child after early, limited anti-HIV treatment. 

Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses
July 24, 2017

Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults. The APPROACH findings, as well as results expected in late 2017 from another early-stage clinical trial called TRAVERSE, will form the basis of the decision whether to move forward with a larger trial in southern Africa to evaluate vaccine safety and efficacy among women at risk of acquiring HIV.

NIH-Supported Scientists Elicit Broadly Neutralizing Antibodies to HIV in Calves
July 20, 2017

Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine design, and support further study of modified bovine antibodies as HIV therapeutics or prevention tools in humans, scientists reported in a paper published online today in Nature.

NIH Statement on HIV Vaccine Awareness Day
May 18, 2017

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesCarl W. Dieffenbach, Ph.D., Director, Division of AIDS, NIAID

NIH Statement on World Tuberculosis Day
March 24, 2017

Statement of Christine F. Sizemore, PhD., Richard Hafner, M.D., and Anthony S. Fauci, M.D. National Institute of Allergy and Infectious DiseasesNational Institutes of Health

Monkeys Suppress HIV-Like Virus for Extended Period after Dual-Antibody Treatment
March 13, 2017

Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.  

NIH Research Helps Explain How Antibody Treatment Led to Sustained Remission of HIV-Like Virus
February 15, 2017

Scientists at the National Institutes of Health have found that the presence of the protein alpha-4 beta-7 integrin on the surface of HIV and its monkey equivalent—simian immunodeficiency virus, or SIV—may help explain why an antibody protected monkeys from SIV in previous experiments. 

NIH Launches First Large Trial of a Long-Acting Injectable Drug for HIV Prevention
December 20, 2016

The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV medication Truvada taken daily as an oral tablet.

NIH Statement on World AIDS Day 2016
December 1, 2016

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesCarl W. Dieffenbach, Ph.D., Director, Division of AIDS, NIAID

First New HIV Vaccine Efficacy Study in Seven Years Has Begun
November 27, 2016

The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus. HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day. 

Antibody VRC01 Safe, Only Modest Effect in Controlling HIV Without Antiretroviral Therapy
November 9, 2016

Infusions of an anti-HIV antibody known as VRC01 were shown to be safe and maintained intended antibody concentrations in the blood of people living with HIV, according to two related studies by scientists at the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG). The antibody modestly suppressed blood levels of HIV in people who stopped taking antiretroviral therapy (ART), but the delay in the reappearance of virus was not clinically significant.

Large Increases in HIV Suppression Needed to Reduce New Infections in Critical Population
October 19, 2016

Achieving moderate reduction of new HIV infections among men who have sex with men (MSM) will depend on significantly increasing the percentage of HIV-infected MSM whose viral load is suppressed to undetectable levels, according to a new mathematical model based on data from Baltimore. Access and adherence to antiretroviral therapy are key to sustained HIV suppression, which dramatically reduces the risk of transmitting HIV to others.

Women Report Vaginal Ring for Preventing HIV Had Little Effect on Sexual Intercourse
October 18, 2016

Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear. This finding is among several insights gleaned about experiences of women who used the ring during the ASPIRE study, also known as MTN-020, announced today at the HIV Research for Prevention (HIVR4P) meeting in Chicago.

Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
October 13, 2016

Scientists at the National Institutes of Health (NIH) and Emory University have experimentally induced sustained remission of SIV, the simian form of HIV, in infected monkeys. The animals’ immune systems have been suppressing the virus to undetectable levels for as long as 23 months since the monkeys completed an investigational treatment regimen. In addition, the regimen has led to the near-complete replenishment of key immune cells that SIV had destroyed, something unachievable with antiretroviral therapy (ART) alone. The findings will be published in the Oct.

NIH-Funded Scientists Identify Immunological Profiles of People Who Make Powerful HIV Antibodies
July 29, 2016

People living with HIV who naturally produce broadly neutralizing antibodies (bNAbs) that may help suppress the virus have different immunological profiles than people who do not, researchers report. While bNAbs cannot completely clear HIV infections in people who have already acquired the virus, many scientists believe a successful preventive HIV vaccine must induce bNAbs

Immune-Enhancing Treatment May Destabilize HIV Reservoirs
July 21, 2016

Although antiretroviral therapy (ART) can reduce the amount of HIV in the blood to an undetectable level in most chronically infected people, it cannot eliminate reservoirs of HIV that persist in latently infected immune cells.

NIH Scientists Discover that Defective HIV DNA Can Encode HIV-Related Proteins
July 18, 2016

Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template for producing HIV-related proteins.

HIV Therapy for Breastfeeding Mothers Can Virtually Eliminate Transmission to Babies
July 18, 2016

For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial conducted in sub-Saharan Africa and India.

Vaginal Ring May Cut HIV Infection Risk if Used Consistently
July 18, 2016

A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent. This finding is being reported today at a press briefing at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa, and will be presented in more detail tomorrow in a lecture at the conference.

NIH Expands Investment in HIV Cure Research
July 13, 2016

The National Institutes of Health has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research.

HIV Vaccine Research Requires Unprecedented Path
July 12, 2016

The development of an effective vaccine to prevent HIV infections would represent a critical step toward ending the HIV/AIDS pandemic. Thus far, the only large clinical trial for an HIV vaccine to show promise was the RV144 study conducted in Thailand in 2009, which resulted in a modest 31 percent reduction in infection. Researchers are working to improve on the results of RV144 and also have launched efforts to create vaccines that induce broadly neutralizing antibodies that can block a wide range of HIV variants.

NIH Statement on HIV Vaccine Awareness Day 2016
May 18, 2016

Advances in HIV/AIDS research have given us the opportunity to transform the lives of those living with HIV while providing highly effective methods of preventing the infection. This progress has strengthened optimism for achieving a durable end to the HIV/AIDS pandemic.

Large-Scale HIV Vaccine Trial to Launch in South Africa
May 18, 2016

An early-stage HIV vaccine clinical trial in South Africa has determined that an investigational vaccine regimen is safe and generates comparable immune responses to those reported in a landmark 2009 study showing that a vaccine can protect people from HIV infection.

NIH-Led Team Discovers New HIV Vaccine Target
May 12, 2016

A team led by scientists at the National Institutes of Health (NIH) has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell.

AIDS-Kaposi’s Sarcoma Study Ended
May 5, 2016

Enrollment into a clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) investigating two different strategies to treat limited-stage AIDS-related Kaposi’s sarcoma was stopped due to futility—if continued, the study would be unlikely to detect a difference between the two study arms.

Single Antibody Infusions Provide Durable Protection Against HIV-Like Virus in Monkeys
April 27, 2016

A single antibody infusion can protect monkeys against infection with an HIV-like virus for up to 23 weeks, researchers have found. The study, published in Nature, was led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and The Rockefeller University.

Animal Study Paints Picture of the Earliest Immune Responses to HIV
April 13, 2016

New research in monkeys exposed to SIV, the monkey equivalent of HIV, suggests that the virus spreads rapidly in the body and triggers early host responses that suppress antiviral immunity, thus promoting viral replication. The study, published in Cell, provides a detailed view of the period between initial mucosal exposure to the virus and the point at which it becomes detectable in the blood.

NIH Launches Large Clinical Trials of Antibody-Based HIV Prevention
April 7, 2016

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the AMP Studies, for antibody-mediated prevention, the trials will test whether giving people an investigational anti-HIV antibody called VRC01 as an intravenous infusion every 8 weeks is safe, tolerable and effective at preventing HIV infection.

AIDS-Kaposi’s Sarcoma Study Changed Due to Drug Underperformance
March 18, 2016

A clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) comparing three advanced Kaposi’s sarcoma chemotherapy regimens in combination with antiretroviral treatment (ART) for patients with AIDS will no longer enroll participants in the study arm testing the oral chemotherapy drug etoposide.

Antibodies from Unconventional B Cells Less Likely to Neutralize HIV, NIH Study Finds
March 17, 2016

Antibodies derived from a type of immune cell found in unusually high numbers in HIV-infected individuals with chronically uncontrolled virus levels are less effective at neutralizing HIV than antibodies derived from a different type of immune cell more common in people without HIV, scientists report. 

Maraviroc-Containing Regimens Safe, Tolerable When Taken for HIV Prevention
February 24, 2016

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV.

NIH-Funded Study Finds Critical Population Adheres to PrEP with Coordinated Care
February 24, 2016

New findings suggest that black men who have sex with men (BMSM) with access to a novel coordinated care program can adhere to pre-exposure prophylaxis (PrEP), a medication regimen that helps prevent HIV infection in uninfected individuals.

Experimental Ebola Vaccines Well Tolerated, Immunogenic in Phase 2 Study
February 23, 2016

Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I.

NIH-Funded Study Finds Effect of PrEP on Bone Density is Reversible
February 23, 2016

The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial
February 22, 2016

A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found.

Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
January 27, 2016

In HIV-infected patients undergoing antiretroviral therapy (ART), ongoing HIV replication in lymphoid tissues such as the lymph nodes helps maintain stores, or reservoirs, of the virus, a new study funded by the National Institutes of Health suggests.

HIV Antibody Infusion Safely Suppresses Virus in Infected People
December 23, 2015

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report. 

NIH Scientists Draw Evidence-Based Blueprint for HIV Treatment and Prevention
December 1, 2015

Scientists from the National Institute of Allergy and Infectious Diseases argue that the results of three large clinical trials definitively prove that the benefits of starting antiretroviral therapy early in HIV infection outweigh any theoretical risk.

NIH Statement on World AIDS Day 2015
November 30, 2015

​When the first cases of what would become known as AIDS were reported in 1981, scientists and physicians did not know the cause and had no therapies to treat those who were infected. Times have changed and today physicians can offer their patients highly effective medicines that work as both treatment and prevention. 

NIH Publishes Criteria for Research on Organ Transplantation Between People with HIV Infection
November 25, 2015

The U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection. 

NIH Launches Initiative to Develop Long-Acting HIV Treatment and Prevention Tools
November 18, 2015

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs)

Immune Responses Provide Clues for HIV Vaccine Development
October 21, 2015

Recent research has yielded new information about immune responses associated with—and potentially responsible for—protection from HIV infection, providing leads for new strategies to develop an HIV vaccine. 

Two Paths Pave Way for Development of a Preventive HIV Vaccine
July 23, 2015

National Institute of Allergy and Infectious Diseases& scientists offer a historical perspective on the search for a safe, effective HIV vaccine and describe how they influence current promising approaches in HIV vaccinology.

HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
July 20, 2015

​Antiretroviral treatment that consistently suppresses HIV is highly effective at preventing sexual transmission of the virus in heterosexual couples where one person is HIV-infected and the other is not, investigators report. ​

Cholesterol Metabolism in Immune Cells Linked to HIV Progression
July 17, 2015

Lower levels of cholesterol in certain immune cells-a result of enhanced cholesterol metabolism within those cells-may help explain why some HIV-infected people are able to naturally control disease progression..

NIAID-Funded HIV Vaccine Research Generates Key Antibodies in Animal Models
June 18, 2015

​A trio of studies describes advances toward the development of an HIV vaccine. The study teams demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.

Anti-HIV Antibody Shows Promise in First Human Study
April 8, 2015

A single infusion of an experimental anti-HIV antibody called 3BNC117 resulted in significantly decreased HIV levels that persisted for as long as 28 days in HIV-infected individuals, according to Phase 1 clinical trial findings published online in Nature. 

NIH Statement on World AIDS Day 2014
December 1, 2014
​Remarkable progress has been made in the fight against HIV/AIDS since the first annual World AIDS Day was commemorated 26 years ago. Yet, we are still far from achieving our goal of a world without AIDS.  
Starting Treatment Soon After HIV Infection Improves Immune Health, Study Finds
November 24, 2014

A study by National Institutes of Health grantees suggests that the best time to start treatment for HIV infection also should be based on how much time has elapsed since becoming HIV-infected.

NIH-Sponsored Study Identifies Superior Drug Regimen for Preventing Mother-to-Child HIV Transmission
November 17, 2014

​For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.

NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns
November 3, 2014

A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period.

Model by NIH Grantees Explains Why HIV Prevention Dosing Differs by Sex
October 30, 2014

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

BULLETIN: In South Africa, RV144 HIV Vaccine Regimen Induces Immune Responses Similar to Those Seen in Thailand
October 28, 2014

​The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa. The results from the trial, called HVTN 097, bode well for plans to test a similar experimental vaccine regimen in South Africa beginning in 2015 in an effort to build upon the results of the RV144 study.

NIH-Led Study Explores Prevention of Heart Disease in HIV-Infected People
October 28, 2014

​The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy (ART) as well as "elite controllers" who can limit the virus without ART, have a higher risk of developing heart disease and stroke compared to the general population. The study is funded by NIH's National Institute of Allergy and Infectious Diseases (NIAID).

NIH-Supported Scientists Unveil Structure, Dynamics of Key HIV Molecules
October 8, 2014

New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects.

"Mississippi Baby" Now Has Detectable HIV, Researchers Find
July 10, 2014
The child known as the “Mississippi baby”—an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall—now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case.   
BULLETIN: NIH Expands Focus of Research Funding Opportunity Targeting HIV Reservoirs
February 25, 2014

The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health, both part of the National Institutes of Health, recently expanded the scientific scope of an HIV-cure related funding announcement to allow for a broader range of studies and approaches.